A strong pipeline for multiple indications
Versantis’ pipeline promises to improve patients’ outcome and relieve health care systems from the economic burden of liver diseases. The lead candidate, VS-01, is the first emergency treatment for acute liver diseases. It is a rescue therapy tackling rare indications of high unmet medical need. It was granted an Orphan Drug Designation which will ensure a fast and lean route to market.
VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both considered as endemic diseases worldwide.
In addition, Versantis continues to expand its strong product pipeline with other products in preclinical development and late stage research for the treatment of metabolic acidemias and for the diagnosis of hyperammonemia.
VS-01: a life-saving therapy
VS-01 is an innovative liposomal-based intra-peritoneal fluid that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during decompensated liver cirrhosis. More specifically, VS-01 clears ammonia from the body, which is the main neurotoxic metabolite leading to hepatic encephalopathy. VS-01 uses a disruptive route of treatment (intraperitoneal) and is the first drug in development to support the liver, the brain, and the kidneys, three organs of major prognostic importance in patients with acute liver diseases. It represents a new hope for these patients.